Clinical trial
Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and…
NCT00191269 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191269 |
|---|---|
| Title | Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen |
| Official title | A Multicenter Study of LY188011 in Anthracyclines and Taxanes Pre-treated Metastatic/Recurrent Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine |
| Enrollment | 68 |
| Start date | Jun 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2010 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 17, 2010 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: